Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer

Inclusion Criteria: * Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum. * Subjects with measurable or unmeasurable disease * Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 * Men or women at least 18 years of age * Adequate hematologic, renal, hepatic and coagulation function Exclusion Criteria: * History or known presence of central nervous system (CNS) metastases * Prior chemotherapy or other systemic therapy for advanced or metastatic CRC * Any investigational agent or therapy for advanced or metastatic CRC * Clinically significant cardiac disease * Clinically significant peripheral neuropathy * Active inflammatory bowel disease * Recent gastrointestinal ulcer or hemorrhage * Recent arterial thrombotic event or pulmonary embolus * Recent history of clinically significant bleeding, bleeding diathesis, or coagulopathy * Recent major surgical procedure or not yet recovered from major surgery